Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
02 2019
Historique:
received: 15 05 2018
revised: 06 08 2018
accepted: 07 12 2018
pubmed: 13 12 2018
medline: 9 4 2020
entrez: 13 12 2018
Statut: ppublish

Résumé

Transforming growth factor β (TGFβ) is an effector of immune suppression and contributes to a permissive tumor microenvironment that compromises effective immunotherapy. We identified a correlation between

Identifiants

pubmed: 30538091
pii: 2326-6066.CIR-18-0310
doi: 10.1158/2326-6066.CIR-18-0310
pmc: PMC6828175
mid: NIHMS1041406
doi:

Substances chimiques

Biomarkers 0
Transforming Growth Factor beta 0
Transforming Growth Factor beta1 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

306-320

Subventions

Organisme : NIH HHS
ID : DP5 OD023056
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA082103
Pays : United States
Organisme : NIH HHS
ID : S10 OD018040
Pays : United States

Informations de copyright

©2018 American Association for Cancer Research.

Références

Proc Natl Acad Sci U S A. 1987 Aug;84(16):5788-92
pubmed: 2886992
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Nature. 2007 Jun 21;447(7147):972-8
pubmed: 17538624
Bioinformatics. 2010 Sep 1;26(17):2176-82
pubmed: 20610611
Cytokine Growth Factor Rev. 2014 Aug;25(4):377-90
pubmed: 25200249
J Clin Invest. 2015 Sep;125(9):3356-64
pubmed: 26168215
Cell Rep. 2016 Dec 20;17(12):3219-3232
pubmed: 28009291
Clin Cancer Res. 2016 Dec 1;22(23):5661-5672
pubmed: 27178742
Oncogene. 2005 Aug 11;24(34):5278-86
pubmed: 16007221
Growth Factors. 2015 Apr;33(2):79-91
pubmed: 25586866
Cancer Res. 2015 Jun 1;75(11):2232-42
pubmed: 25858148
J Immunol. 2008 Oct 1;181(7):4666-75
pubmed: 18802069
J Mol Cell Biol. 2013 Jun;5(3):207-9
pubmed: 23532593
Science. 2015 Jul 10;349(6244):1259425
pubmed: 26160952
Nature. 2016 Nov 17;539(7629):443-447
pubmed: 27828943
J Exp Med. 2008 Sep 29;205(10):2235-49
pubmed: 18809714
Nat Rev Immunol. 2012 Jan 06;12(2):125-35
pubmed: 22222875
Cell. 2016 May 5;165(4):780-91
pubmed: 27153492
J Immunol. 2010 Aug 15;185(4):2273-84
pubmed: 20644162
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
J Immunol. 2007 Mar 1;178(5):2883-92
pubmed: 17312132
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Am J Respir Cell Mol Biol. 2002 Feb;26(2):224-30
pubmed: 11804874
J Cell Mol Med. 2005 Jan-Mar;9(1):59-71
pubmed: 15784165
J Immunol. 2006 Jul 1;177(1):216-26
pubmed: 16785517
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Cytometry A. 2012 Jun;81(6):467-75
pubmed: 22577098
J Transl Med. 2011 Jun 09;9:90
pubmed: 21658270
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Cancer Discov. 2014 Oct;4(10):1230-41
pubmed: 25084773
Nature. 2017 Mar 30;543(7647):728-732
pubmed: 28321130
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
J Immunol. 2003 Apr 1;170(7):3806-11
pubmed: 12646647
Clin Cancer Res. 2015 Feb 1;21(3):553-60
pubmed: 25424852
Nat Med. 2015 Jul;21(7):677-87
pubmed: 26121197
Cancer Cell. 2013 Jun 10;23(6):768-83
pubmed: 23764001
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Mol Cell Biol. 2009 Nov;29(22):6006-17
pubmed: 19752192
Mol Cell Biol. 2009 Jan;29(1):172-86
pubmed: 18955504
Cancer Immunol Res. 2016 Jul;4(7):592-9
pubmed: 27197061
Clin Cancer Res. 2011 Nov 1;17(21):6754-65
pubmed: 22028490
Cytokine Growth Factor Rev. 2017 Aug;36:5-15
pubmed: 28693973
J Immunol. 2012 Jun 1;188(11):5500-10
pubmed: 22544933
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Curr Opin Pharmacol. 2009 Aug;9(4):470-81
pubmed: 19616475
Oncol Lett. 2011 Jul;2(4):583-589
pubmed: 22848232
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nat Methods. 2015 Feb;12(2):115-21
pubmed: 25633503
Blood Cells Mol Dis. 2007 Nov-Dec;39(3):329-35
pubmed: 17659913
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
PLoS One. 2016 Oct 25;11(10):e0164514
pubmed: 27780254
Nat Rev Cancer. 2013 Nov;13(11):788-99
pubmed: 24132110
Nat Rev Drug Discov. 2012 Oct;11(10):790-811
pubmed: 23000686
Eur J Immunol. 2004 May;34(5):1342-50
pubmed: 15114667
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):91-9
pubmed: 25835621
Nat Med. 2004 Jan;10(1):48-54
pubmed: 14702634
BMC Immunol. 2012 Jun 15;13:31
pubmed: 22703233
Cancer Res. 2012 Aug 15;72(16):4119-29
pubmed: 22693253
Trends Immunol. 2011 Jan;32(1):19-25
pubmed: 21067974

Auteurs

Alba Gonzalez-Junca (A)

Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Kyla E Driscoll (KE)

TGFβ and Tumor Microenvironment, Eli Lilly and Company, New York, New York.

Ilenia Pellicciotta (I)

Department of Radiation Oncology, New York University School of Medicine, New York, New York.

Shisuo Du (S)

Department of Radiation Oncology, New York University School of Medicine, New York, New York.

Chen Hao Lo (CH)

Department of Radiation Oncology, New York University School of Medicine, New York, New York.
Department of Tumor Biology, Moffitt Cancer Center, Tampa, Florida.

Ritu Roy (R)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Computational Biology and Informatics (CBI), University of California San Francisco, San Francisco, California.

Renate Parry (R)

Varian Medical Systems, Inc., Palo Alto, California.

Iliana Tenvooren (I)

Parker Institute for Cancer Immunotherapy, Department of Otolaryngology-Head and Neck Surgery, Department of Microbiology and Immunology, UCSF School of Medicine, San Francisco, California.

Diana M Marquez (DM)

Parker Institute for Cancer Immunotherapy, Department of Otolaryngology-Head and Neck Surgery, Department of Microbiology and Immunology, UCSF School of Medicine, San Francisco, California.

Matthew H Spitzer (MH)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Parker Institute for Cancer Immunotherapy, Department of Otolaryngology-Head and Neck Surgery, Department of Microbiology and Immunology, UCSF School of Medicine, San Francisco, California.

Mary Helen Barcellos-Hoff (MH)

Department of Radiation Oncology, University of California San Francisco, San Francisco, California. Mary.Barcellos-Hoff@ucsf.edu.
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH